TAXOTERE (docetaxel) injection prescribing information, revised 01/2023 (2023)

Government Record · sanofi-aventis U.S. LLC (manufacturer's label approved by FDA) · January 2023

sanofi-aventis U.S. LLC (manufacturer's label approved by FDA), 2023-01: The current FDA-approved Taxotere label limits the prostate indication to metastatic castration-resistant disease in combination with prednisone, dosed at 75 mg/m2 every three weeks; there is no localized-disease indication.

TAXOTERE in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.

4

sanofi-aventis U.S. LLC (manufacturer's label approved by FDA), 2023-01: The current FDA-approved Taxotere label limits the prostate indication to metastatic castration-resistant disease in combination with prednisone, dosed at 75 mg/m2 every three weeks; there is no localized-disease indication. Funder: n/a (label). Maker: sanofi-aventis U.S. LLC (address block, p. last). Comparator: n/a. Label revised 01/2023, supplement 086. Current as of this run (Nov 2026); FDA lists 01/18/2023 as the most recent labeling action on NDA 020449. Study type: regulatory record.